Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma

Riudavets, Mariona; Majem, Margarita; Bosch-Barrera, Joaquim; Cabezón-Gutiérrez, Luís; Diz Taín, Pilar; Hernández, Ainhoa; Morán, Teresa; Alonso, Miriam; Blanco, Remei; Gálvez, Elisa.
Clin. transl. oncol. (Print) ; 23(12): 2560-2567, dec. 2021. graf
Artículo en Inglés | IBECS (España) | ID: ibc-224113

Documentos relacionados

  1. Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching.
  2. Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report.
  3. A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
  4. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
  5. Albumin-to-D-dimer ratios: A novel prognostic factor for evaluating first-line chemotherapy efficacy in advanced lung adenocarcinoma patients.
  6. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
  7. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma.
  8. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
  9. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
  10. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.